Histosonics Inc. Histotripsy, developed by ultrasound scientists from the University of Michigan, offers a non-invasive alternative to certain surgical procedures. Through ongoing collaborations with leading multi-disciplinary clinicians from the University of Wisconsin and the University of Michigan, Histosonics is working to translate the science of histotripsy into everyday clinical practice.

Their goal is to make this innovative technology accessible to patients around the world. The company is led by a skilled executive team, including Mike Blue as President and CEO, and a Board of Directors with deep experience in medical technology. Histosonics is also supported by renowned venture capital and healthcare investors who have a track record of building successful organizations in the field.

With their commitment to advancing medical technology, Histosonics is dedicated to improving patient outcomes and revolutionizing the way physicians deliver care